Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy

REFERENCES

• Pages F, Kirilovsky A, Mlecnik B, In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944–5951.
   Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220–5227.
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJ, de Jong RA, Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58:449–459.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538–18543.
   PubMed Web of Science ®Google Scholar
• Kondratiev S, Sabo E, Yakirevich E, Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450–4456.
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB, Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903–907.
   PubMed Web of Science ®Google Scholar
• Watson NF, Ramage JM, Madjd Z, Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006;118:6–10.
   PubMed Web of Science ®Google Scholar
• Atkins D, Breuckmann A, Schmahl GE, MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004;109:265–273.
   PubMed Web of Science ®Google Scholar
• Tourkova IL, Shurin GV, Ferrone S, Shurin MR. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother 2009;58:567–574.
   Google Scholar
• Cathro HP, Smolkin ME, Theodorescu D, Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 2010;59:465–472.
   Google Scholar
• Dart LL, Smith DM, Meyers CA, Transforming growth factors from a human tumor cell: Characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry 1985;24:5925–5931.
   Google Scholar
• O’Garra A, Stapleton G, Dhar V, Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990;2:821–832.
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Yang SC, Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961–968.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Liu X, Gao JX, Wen J, B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003;197:1721–1730.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712–4717.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Immunological self-tolerance maintained by activated T-cells expressing Il-2 receptor alpha-chains (Cd25)—Breakdown of a single mechanism of self-tolerance causes various autoimmune-diseases. J Immunol 1995;155:1151–1164.
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3 +regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469–1480.
   PubMed Web of Science ®Google Scholar
• Wang XN, Haniffa MA, Holtick U, Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation 2009;88:188–197.
   Google Scholar
• Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 2007;56:271–285.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.
   PubMed Web of Science ®Google Scholar
• Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983–2990.
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, Van Der Voort EIH, Transient expression of FOXP3 in human activated nonregulatory CD4(+) T cells. Euro J Immunol 2007;37:129–138.
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404–4408.
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Hillemann T, Wedemeyer H, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457–2464.
   PubMed Web of Science ®Google Scholar
• Karube K, Ohshima K, Tsuchiya T, Expression of FoxP3, a key molecule in CD4(+)CD25(+) regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004;126:81–84.
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766–4772.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Christie LE, Munro LR, Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755–1762.
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O, Foxp3 expressing CD4(+)CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444–1453.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou LH, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–949.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Chemokine biology in cancer. Semin Immunol 2003;15:49–55.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
   PubMed Web of Science ®Google Scholar
• Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002;72:9–18.
   PubMed Web of Science ®Google Scholar
• Belperio JA, Keane MP, Arenberg DA, CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1–8.
   PubMed Web of Science ®Google Scholar
• Luan J, Shattuck-Brandt R, Haghnegahdar H, Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997;62:588–597.
   PubMed Web of Science ®Google Scholar
• Takamori H, Oades ZG, Hoch OC, Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 2000;21:52–56.
   PubMed Web of Science ®Google Scholar
• Berin MC, Eckmann L, Broide DH, Kagnoff MF. Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell & Mol Biol 2001;24:382–389.
   PubMed Web of Science ®Google Scholar
• Hagemann T, Wilson J, Burke F, Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006;176:5023–5032.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Imaizumi K, Hasegawa Y, Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother 2006;55:1320–1329.
   Google Scholar
• Qin XJ, Shi HZ, Deng JM, CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009;15:2231–2237.
   PubMed Web of Science ®Google Scholar
• Takegawa S, Jin Z, Nakayama T, Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci 2008;99:296–302.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Kono K, Izawa S, CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus 2010;23(5):422–429.
   Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000–2009.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kono K, Kawaguchi Y, CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3(+) regulatory T cells in gastric cancer. Int J Cancer 2008;122:2286–2293.
   PubMed Web of Science ®Google Scholar
• Cornforth AN, Lee GJ, Fowler AW, Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. J Clin Immunol 2009;29:657–664.
   Google Scholar
• Iellem A, Mariani M, Lang R, Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exper Med 2001;194:847–853.
   PubMed Web of Science ®Google Scholar
• Niens M, Visser L, Nolte IM, Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 2008;140:527–536.
   PubMed Web of Science ®Google Scholar
• Bernardini G, Hedrick J, Sozzani S, Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. Eur J Immunol 1998;28:582–588.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Kawamura YI, Yasuhara M, Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. J Immunol 2007;178:5296–5304.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Walter S, Govoni D, Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992;148:1280–1285.
   PubMed Web of Science ®Google Scholar
• Carr MW, Roth SJ, Luther E, Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994;91:3652–3656.
   PubMed Web of Science ®Google Scholar
• Metelitsa LS, Wu HW, Wang H, Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004;199:1213–1221.
   PubMed Web of Science ®Google Scholar
• Mizutani K, Sud S, McGregor NA, The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009;11:1235–1242.
   Google Scholar
• Li X, Loberg R, Liao J, A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009;69:1685–1692.
   Google Scholar
• Cai Z, Chen Q, Chen J, Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia 2009;11:228–236.
   PubMed Web of Science ®Google Scholar
• Jordan JT, Sun W, Hussain SF, Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123–131.
   PubMedGoogle Scholar
• Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010;21(1):41–48.
   PubMed Web of Science ®Google Scholar
• Chavey C, Bibeau F, Gourgou-Bourgade S, Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007;9:R15.
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Asosingh K, Vanderkerken K, Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855–862.
   Google Scholar
• Torisu H, Ono M, Kiryu H, Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85:182–188.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Lutz M, The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676–1686.
   PubMed Web of Science ®Google Scholar
• Schimanski CC, Schwald S, Simiantonaki N, Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res2005;11:1743–1750.
   PubMed Web of Science ®Google Scholar
• Zou L, Barnett B, Safah H, Bone marrow is a reservoir for CD4+CD25 +regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004;64:8451–8455.
   PubMed Web of Science ®Google Scholar
• Grauer OM, Nierkens S, Bennink E, CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121:95–105.
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Edwards RP, Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007;67:7487–7494.
   PubMed Web of Science ®Google Scholar
• Sasada T, Kimura M, Yoshida Y, CD4(+)CD25(+) regulatory T cells in patients with gastrointestinal malignancies—Possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089–1099.
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287–296.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kuniyasu Y, Toda M, Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969–1980.
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Rasmussen JP, Chi EY, Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:546–558.
   PubMed Web of Science ®Google Scholar
• Ise W, Kohyama M, Nutsch KM, CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010;11:129–135.
   PubMed Web of Science ®Google Scholar
• Chen C, Rowell EA, Thomas RM, Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 2006;281:36828–36834.
   PubMedGoogle Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061.
   PubMed Web of Science ®Google Scholar
• Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exper Med 2000;192:295–302.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S, Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exper Med 2000;192:303–309.
   PubMed Web of Science ®Google Scholar
• Collins AV, Brodie DW, Gilbert RJ, The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201–210.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Tan P, Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992;176:1595–1604.
   PubMed Web of Science ®Google Scholar
• Vandenborre K, Van Gool SW, Kasran A, Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999;98:413–421.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271–275.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Gribben JG, Boussiotis VA, Cloning of B7–2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909–911.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4:1206–1212.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069–1077.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629–644.
   PubMed Web of Science ®Google Scholar
• Green EA, Gorelik L, McGregor CM, CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 2003;100:10878–10883.
   PubMed Web of Science ®Google Scholar
• Bopp T, Becker C, Klein M, Cyclic adenosine monophosphate is a key component of regulatory T cell mediated suppression. J Exper Med 2007;204:1303–1310.
   PubMed Web of Science ®Google Scholar
• Hoskin DW, Mader JS, Furlong SJ, Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008;32:527–535.
   PubMed Web of Science ®Google Scholar
• Bodor J, Fehervari Z, Diamond B, Sakaguchi S. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 2007;37:884–895.
   PubMed Web of Science ®Google Scholar
• Oberle N, Eberhardt N, Falk CS, Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: Independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol 2007;179:3578–3587.
   PubMed Web of Science ®Google Scholar
• Bodor J, Habener JF. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. J Biol Chem 1998;273:9544–9551.
   PubMedGoogle Scholar
• Grossman WJ, Verbsky JW, Barchet W, Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004;21:589–601.
   PubMed Web of Science ®Google Scholar
• Gondek DC, Lu LF, Quezada SA, Cutting edge: Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005;174:1783–1786.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Lange A, Mottram P, CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465–472.
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Wolfl M, Jonuleit H, Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772–4780.
   PubMed Web of Science ®Google Scholar
• Harizi H, Juzan M, Pitard V, Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002;168:2255–2263.
   PubMed Web of Science ®Google Scholar
• Geissmann F, Revy P, Regnault A, TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567–4575.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010;117:366–372.
   PubMed Web of Science ®Google Scholar
• Sheu BC, Chang WC, Cheng CY, Cytokine regulation networks in the cancer microenvironment. Front Biosci 2008;13:6255–6268.
   PubMed Web of Science ®Google Scholar
• Groux H, O’Garra A, Bigler M, A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–742.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kitani A, Fuss I, TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834–842.
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566–569.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257–1265.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213–1222.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L, Cutting edge: Induction of B7-H4 on APCs through IL-10: Novel suppressive mode for regulatory T cells. J Immunol 2006;177:40–44.
   PubMed Web of Science ®Google Scholar
• de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4(+)CD25(+) regulatory T cell function. Euro J Immunol 2004;34:2480–2488.
   PubMed Web of Science ®Google Scholar
• Barthlott T, Moncrieffe H, Veldhoen M, CD25(+)CD4(+) T cells compete with naive CD4(+) T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 2005;17:279–288.
   PubMed Web of Science ®Google Scholar
• Zambricki E, Shigeoka A, Kishimoto H, Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 2005;5:2623–2631.
   PubMed Web of Science ®Google Scholar
• McDonald SA, Palmen MJ, Van Rees EP, MacDonald TT. Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology 1997;91:73–80.
   Google Scholar
• Yates J, Rovis F, Mitchell P, The maintenance of human CD4+ CD25 +regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 2007;19:785–799.
   PubMed Web of Science ®Google Scholar
• Bayry J, Tchilian EZ, Davies MN, In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A 2008;105:10221–10226.
   PubMed Web of Science ®Google Scholar
• Andrews G, Jones C, Wreggett KA. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 2008;73:855–867.
   PubMed Web of Science ®Google Scholar
• Kang S, Xie J, Ma S, Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 2010;215:153–162.
   Google Scholar
• Baatar D, Olkhanud P, Newton D, CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007;179:1996–2004.
   PubMedGoogle Scholar
• Olkhanud PB, Baatar D, Bodogai M, Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009;69:5996–6004.
   Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010;28:1591–1598.
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520–1531.
   PubMed Web of Science ®Google Scholar
• Sebastiani S, Allavena P, Albanesi C, Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 2001;166:996–1002.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Buchlis G, Kapoor V, CCL2 blockade augments cancer immunotherapy. Cancer Res 2010;70:109–118.
   Google Scholar
• Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009;19:295–303.
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Smeets TJ, A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2387–2392.
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptor antagonists: Overcoming developmental hurdles. Nat Rev Drug Discov 2009;8:23–33.
   PubMed Web of Science ®Google Scholar
• Azab AH, Runnels JM, Pitsillides C, CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113:4341–4351.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 [E-pub ahead of print].
   Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043–6053.
   PubMed Web of Science ®Google Scholar
• Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009;24:321–325.
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S, Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120:2723–2733.
   PubMed Web of Science ®Google Scholar
• Attia P, Maker AV, Haworth LR, Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582–592.
   PubMed Web of Science ®Google Scholar
• Gerena-Lewis M, Crawford J, Bonomi P, A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol 2009;32:269–273.
   PubMed Web of Science ®Google Scholar
• Cho JS, Hsu JV, Morrison SL. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. Cancer Immunol Immunother 2009;58:1057–1069.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3;135–142.
   PubMed Web of Science ®Google Scholar
• Tone M, Tone Y, Adams E, Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003;100:15059–15064.
   PubMed Web of Science ®Google Scholar
• Sonawane SB, Kim JI, Lee MK, GITR blockade facilitates Treg mediated allograft survival. Transplantation 2009;88:1169–1177.
   Google Scholar
• Cohen AD, Diab A, Perales MA, Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006;66:4904–4912.
   PubMed Web of Science ®Google Scholar
• Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006;176:6434–6442.
   PubMed Web of Science ®Google Scholar
• Zhou P, L’Italien S, Hodges D, Schebye XM. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007;179:7365–7375.
   PubMed Web of Science ®Google Scholar
• Mitsui J, Nishikawa H, Muraoka D, Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010;16:2781–2791.
   PubMed Web of Science ®Google Scholar
• Coe D, Begom S, Addey C, Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010;59(9):1367–1377.
   PubMed Web of Science ®Google Scholar
• Takeda I, Ine S, Killeen N, Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004;172:3580–3589.
   PubMed Web of Science ®Google Scholar
• Vu MD, Xiao X, Gao W, OX40 costimulation turns off Foxp3+ Tregs. Blood 2007;110:2501–2510.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Hori T, Yanagita S, Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo. Exp Hematol 2005;33:336–343.
   Google Scholar
• Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825–839.
   PubMed Web of Science ®Google Scholar
• Yokouchi H, Yamazaki K, Chamoto K, Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 2008;99:361–367.
   Google Scholar
• Pisters PW, Patel SR. Gastrointestinal stromal tumors: Current management. J Surg Oncol 2010 [E-pub ahead of print].
   Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J, Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883–1887.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Beppu K, Jaboine J, Merchant MS, Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46–55.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–337.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323–328.
   PubMed Web of Science ®Google Scholar
• Wang WL, Healy ME, Sattler M, Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521–3528.
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Lore K, Greiner E, Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473–2479.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Souan L, Knutson GJ, Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104:1094–1099.
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhao W, Meng F, Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2010;135:55–62.
   PubMed Web of Science ®Google Scholar
• Larmonier N, Janikashvili N, LaCasse CJ, Imatinib mesylate inhibits CD4 +CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 2008;181:6955–6963.
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–2522.
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148–2157.
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674–6682.
   PubMed Web of Science ®Google Scholar
• Apostolou I, Sarukhan A, Klein L, and von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002;3:756–763.
   PubMed Web of Science ®Google Scholar
• Degauque N, Lair D, Braudeau C, Development of CD25(-) regulatory T cells following heart transplantation: Evidence for transfer of long-term survival. Euro J Immunol 2007;37:147–156.
   Google Scholar
• Shevach EM. CD4(+)CD25(+) suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389–400.
   PubMed Web of Science ®Google Scholar
• Kuniyasu Y, Takahashi T, Itoh M, Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000;12:1145–1155.
   PubMed Web of Science ®Google Scholar
• Jiang H, Ware R, Stall A, Murine Cd8(+) T-cells that specifically delete autologous Cd4(+) T-cells expressing V-beta-8 Tcr—A role of the Q-alpha-1 molecule. Immunity 1995;2:185–194.
   PubMed Web of Science ®Google Scholar
• Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NSF. CD8(+)CD28(-) T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001;182:201–206.
   PubMed Web of Science ®Google Scholar
• Sobhani I, Le Gouvello S. Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans. Gut 2009;58:743–744.
   Google Scholar
• Bates GJ, Fox SB, Han C, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–5380.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6(+)Foxp3(+) regulatory T cells in the tumor mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clin Immunol 2010;135(3):466–475.
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326–8331.
   PubMed Web of Science ®Google Scholar
• Li JF, Chu YW, Wang GM, The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int 2009;103:399–405.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–192.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Chikazawa N, Tasaka T, Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2010;59(5):653–661.
   Google Scholar
• Loddenkemper C, Schernus M, Noutsias M, In situ analysis of FOXP3 +regulatory T cells in human colorectal cancer. J Transl Med 2006;4:52.
   PubMedGoogle Scholar
• Sinicrope FA, Rego RL, Ansell SM, Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009;137:1270–1279.
   PubMed Web of Science ®Google Scholar
• Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006;12:3355–3360.
   PubMed Web of Science ®Google Scholar
• de Jong RA, Leffers N, Boezen HM, Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 2009;114:105–110.
   Google Scholar
• Fu J, Xu D, Liu Z, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328–2339.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586–2593.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957–2964.
   PubMed Web of Science ®Google Scholar
• Kelley TW, Pohlman B, Elson P, His ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958–965.
   PubMed Web of Science ®Google Scholar
• Perrone G, Ruffini PA, Catalano V, Intratumoral FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008;44;1875–1882.
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhou S, Wang Y, Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8 +ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol [E-pub ahead of print].
   Google Scholar
• Meagher C, Arreaza G, Peters A, CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses. Diabetes 2007;56:809–817.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Bromley SK, Means TK, CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 2007;204:1327–1334.
   Google Scholar
• Schnickel GT, Bastani S, Hsieh GR, Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008;180:4714–4721.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang N, Fu S, CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 2006;55:1011–1021.
   PubMedGoogle Scholar
• Muller M, Carter SL, Hofer MJ, CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007;179:2774–2786.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Inoue A, Muraoka M, Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice. Arthritis Res Ther 2007;9:R15.
   Google Scholar
• Moreira AP, Cavassani KW, Massafera Tristao FS, CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression. J Immunol 2008;180:3049–3056.
   PubMed Web of Science ®Google Scholar
• Nguyen KD, Fohner A, Booker JD, XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthma. J Immunol 2008;181:5386–5395.
   PubMed Web of Science ®Google Scholar